Category: Award

BI would like to congratulate EI Therapeutics on making the 2025 Renaissance Ventures HotList! The HotList represents high-promise, early-stage companies expected to raise venture capital within the next 12-18 months.

Election to the National Academy of Engineering is among the highest professional distinctions accorded to an engineer. Academy membership honors those who have made outstanding contributions in at least one of the following categories: “engineering practice, research, or education”, “pioneering of new and developing fields of technology, major advancements in traditional fields of engineering, or development/implementation of innovative approaches to engineering education” or “engineering leadership of one or more major endeavors.”

“I’m thrilled to be presenting the Turnbull Lecture this year. The annual Fall MRS meeting is always a great opportunity to share and learn about the latest exciting developments in materials research.” – Dr. Sharon Glotzer

Congratulations to Department Chair of Chemical Engineering, Dr. Sharon Glotzer, on being awarded the 2025 Irving Langmuir Award in Chemical Physics for demonstrating the critical role of shape entropy in colloidal assembly.

We are pleased to announce that EI Therapeutics (a startup spun out of BI) has been named the Runner Up for the Audience Choice Award at the Nucleate Midwest Showcase 2024! Congratulations to Priyan Weerappuli (BI postdoc) and Sam Currier (UM MBA student)!

This award is presented to those faculty that showed significant contributions and leadership in fields ranging from firearm injury prevention and multi-scale computation to Earth remote sensing and molecular imaging. Dr. Luker’s work focuses on the discovery of how cell surface receptors for chemokines and growth factors regulate breast cancer metastasis, and how they are regulated by the tumor microenvironment and metabolic environment.

“We recently assembled a team of 6 labs from the US, Australia, and France to develop a method of probing the brain to assess seizure risk in real time. We will test our method using advanced data analysis, four animal models, and a pilot human study. The results would pionner a new method of testing whether seizure treatments work wihtout waiting for seizures to occur, allowing efficient treatment optimization. We named our project PREMONITION: PREictal MONitoring of seIzure risk for Treatment optimizatION” – William Stacey

“Our team developed a non-viral gene delivery platform that is free from immune response. This platform will allow us to advance the gene therapy path for xerostomia. Through the Frankel Innovation Initiative program, we aim to finalize preclinical studies to enable our FDA IND filing to support a first-in-human trial.” – Isabelle Lombaert

Yesterday, BI hosted our annual research day.  It was a day of sharing knowledge and connecting with collaborators and colleagues to accelerate future research efforts.